Twirla (levonorgestrel and ethinyl estradiol) transdermal system is now available as a method of contraception for use in women of reproductive potential with a BMI Twirla® (levonorgestrel and ethinyl ...

PRINCETON, N.J., April 30, 2021 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that a post hoc analysis of the Phase 3 SECURE Trial ...

NORTH WALES, Pa., Sept. 24, 2013 /PRNewswire/ -- Teva Women's Health, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd., today announced that the recently approved Quartette™ ...

TWIRLA is indicated as a method of contraception for use in women of reproductive potential with a BMI 30 kg/m2 for whom a combined hormonal contraceptive is appropriate. Limitations of Use Consider ...

The renewed partnership between Afaxys and Exeltis underscores both organizations' ongoing commitment to expanding access to innovative contraceptive options within the U.S. public health market, like ...

Once-WeeklyTwirla is the first and only contraceptive patch that combines levonorgestrel and ethinyl estradiol (EE) PRINCETON, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: ...

Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its New ...

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment. Very ...

A model assessing 8 hormonal contraceptive methods found that lower pregnancy costs for the etonogestrel implant and levonorgestrel intrauterine device offset their higher acquisition costs. To ...

Glenmark Pharmaceuticals Ltd has informed BSE regarding a Press Release dated April 10, 2015, titled "Glenmark Generics receives ANDA approval for Levonorgestrel and Ethinyl Estradiol Tablets USP, ...

Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq: AGRX) (Agile or the Company), a ...

FRAZER, Pa.--(BUSINESS WIRE)--Teva Women’s Health, Inc., a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) ...